| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10036449 | HBV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS10050122 | HBV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS30085065 | HIV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20007380 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20007381 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20010779 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20035928 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20057329 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20021555 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20056904 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HRH1 |
|---|---|
| DrugBank ID | DB00455 |
| Drug Name | Loratadine |
| Target ID | BE0000442 |
| UniProt ID | P35367 |
| Regulation Type | antagonist |
| PubMed IDs | 11752352; 1303772; 7581058; 8174605; 10597865; 15942272; 1303773; 9444440; 1977506 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Cieslewicz G, Gondorowicz K, Grzelewska-Rzymowska I, Rozniecki J, Wojciechowska B: [Effect of loratadine--selective antagonist of histamine (H1) receptor--on allergen-induced bronchoconstriction in atopic asthmatics]. Pneumonol Alergol Pol. 1992;60(11-12):11-5.@@Cieslewicz G, Gondorowicz K, Grzelewska-Rzymowska I, Rozniecki J: [Effect of loratadine, selective antagonist of histamine H1 receptors, on histamine-induced bronchoconstriction]. Pneumonol Alergol Pol. 1995;63(5-6):281-5.@@Letari O, Miozzo A, Folco G, Belloni PA, Sala A, Rovati GE, Nicosia S: Effects of loratadine on cytosolic Ca2+ levels and leukotriene release: novel mechanisms of action independent of the anti-histamine activity. Eur J Pharmacol. 1994 Feb 15;266(3):219-27.@@Cavero I, Mestre M, Guillon JM, Heuillet E, Roach AG: Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans? Drug Saf. 1999;21 Suppl 1:19-31; discussion 81-7.@@Tamura T, Masaki S, Ohmori K, Karasawa A: Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Pharmacology. 2005 Dec;75(1):45-52. Epub 2005 Jun 7.@@Grzelewska-Rzymowska I, Gondorowicz K, Cieslewicz G, Rozniecki J, Wojciechowska B: [Effect of loratadine (LO), a selective H1 antagonist, on histamine-induced bronchoconstriction]. Pneumonol Alergol Pol. 1992;60(11-12):16-21.@@Menardo JL, Horak F, Danzig MR, Czarlewski W: A review of loratadine in the treatment of patients with allergic bronchial asthma. Clin Ther. 1997 Nov-Dec;19(6):1278-93; discussion 1523-4.@@Howarth PH: Histamine and asthma: an appraisal based on specific H1-receptor antagonism. Clin Exp Allergy. 1990 Aug;20 Suppl 2:31-41. |
| Groups | Approved; Investigational |
| Direct Classification | Benzocycloheptapyridines |
| SMILES | CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2 |
| Pathways | Loratadine H1-Antihistamine Action |
| PharmGKB | PA450266 |
| ChEMBL | CHEMBL998 |
